Transforming the Activation of Clinical Trials

Julie T. Watters, Jason H. Pitzen, Linda J. Sanders, Virginia Nickie M. Bruce, Alissa R. Cornell, Gary C. Cseko, Janice S. Grace, Pamela S. Kwon, Andrea K. Kukla, Michael S. Lee, Michelle D. Monosmith, John D. Myren, Rebecca S. Kottschade, Marc N. Shaft, Jennifer Jenny A. Weis, Jane C. Welter, Adil Eddie Bharucha

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The Institute of Medicine and US Food and Drug Administration (FDA) recognize that activating clinical trials in the United States is lengthy and inefficient. Downstream consequences include increased expense, suboptimal accrual, move of clinical trials overseas, and delayed availability of treatments for patients. An in-tandem processing initiative is here highlighted that transformed the activation of clinical trials (TACT), reduced the activation time by 70%, and offers a paradigm for enhanced translational readiness.

Original languageEnglish (US)
Pages (from-to)43-46
Number of pages4
JournalClinical Pharmacology and Therapeutics
Volume103
Issue number1
DOIs
StatePublished - Jan 1 2018

Fingerprint

National Academies of Science, Engineering, and Medicine (U.S.) Health and Medicine Division
Clinical Trials
United States Food and Drug Administration
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Watters, J. T., Pitzen, J. H., Sanders, L. J., Bruce, V. N. M., Cornell, A. R., Cseko, G. C., ... Bharucha, A. E. (2018). Transforming the Activation of Clinical Trials. Clinical Pharmacology and Therapeutics, 103(1), 43-46. https://doi.org/10.1002/cpt.898

Transforming the Activation of Clinical Trials. / Watters, Julie T.; Pitzen, Jason H.; Sanders, Linda J.; Bruce, Virginia Nickie M.; Cornell, Alissa R.; Cseko, Gary C.; Grace, Janice S.; Kwon, Pamela S.; Kukla, Andrea K.; Lee, Michael S.; Monosmith, Michelle D.; Myren, John D.; Kottschade, Rebecca S.; Shaft, Marc N.; Weis, Jennifer Jenny A.; Welter, Jane C.; Bharucha, Adil Eddie.

In: Clinical Pharmacology and Therapeutics, Vol. 103, No. 1, 01.01.2018, p. 43-46.

Research output: Contribution to journalArticle

Watters, JT, Pitzen, JH, Sanders, LJ, Bruce, VNM, Cornell, AR, Cseko, GC, Grace, JS, Kwon, PS, Kukla, AK, Lee, MS, Monosmith, MD, Myren, JD, Kottschade, RS, Shaft, MN, Weis, JJA, Welter, JC & Bharucha, AE 2018, 'Transforming the Activation of Clinical Trials', Clinical Pharmacology and Therapeutics, vol. 103, no. 1, pp. 43-46. https://doi.org/10.1002/cpt.898
Watters JT, Pitzen JH, Sanders LJ, Bruce VNM, Cornell AR, Cseko GC et al. Transforming the Activation of Clinical Trials. Clinical Pharmacology and Therapeutics. 2018 Jan 1;103(1):43-46. https://doi.org/10.1002/cpt.898
Watters, Julie T. ; Pitzen, Jason H. ; Sanders, Linda J. ; Bruce, Virginia Nickie M. ; Cornell, Alissa R. ; Cseko, Gary C. ; Grace, Janice S. ; Kwon, Pamela S. ; Kukla, Andrea K. ; Lee, Michael S. ; Monosmith, Michelle D. ; Myren, John D. ; Kottschade, Rebecca S. ; Shaft, Marc N. ; Weis, Jennifer Jenny A. ; Welter, Jane C. ; Bharucha, Adil Eddie. / Transforming the Activation of Clinical Trials. In: Clinical Pharmacology and Therapeutics. 2018 ; Vol. 103, No. 1. pp. 43-46.
@article{96bd048708fb4b2eb21c4cf4d06d9086,
title = "Transforming the Activation of Clinical Trials",
abstract = "The Institute of Medicine and US Food and Drug Administration (FDA) recognize that activating clinical trials in the United States is lengthy and inefficient. Downstream consequences include increased expense, suboptimal accrual, move of clinical trials overseas, and delayed availability of treatments for patients. An in-tandem processing initiative is here highlighted that transformed the activation of clinical trials (TACT), reduced the activation time by 70{\%}, and offers a paradigm for enhanced translational readiness.",
author = "Watters, {Julie T.} and Pitzen, {Jason H.} and Sanders, {Linda J.} and Bruce, {Virginia Nickie M.} and Cornell, {Alissa R.} and Cseko, {Gary C.} and Grace, {Janice S.} and Kwon, {Pamela S.} and Kukla, {Andrea K.} and Lee, {Michael S.} and Monosmith, {Michelle D.} and Myren, {John D.} and Kottschade, {Rebecca S.} and Shaft, {Marc N.} and Weis, {Jennifer Jenny A.} and Welter, {Jane C.} and Bharucha, {Adil Eddie}",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/cpt.898",
language = "English (US)",
volume = "103",
pages = "43--46",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Transforming the Activation of Clinical Trials

AU - Watters, Julie T.

AU - Pitzen, Jason H.

AU - Sanders, Linda J.

AU - Bruce, Virginia Nickie M.

AU - Cornell, Alissa R.

AU - Cseko, Gary C.

AU - Grace, Janice S.

AU - Kwon, Pamela S.

AU - Kukla, Andrea K.

AU - Lee, Michael S.

AU - Monosmith, Michelle D.

AU - Myren, John D.

AU - Kottschade, Rebecca S.

AU - Shaft, Marc N.

AU - Weis, Jennifer Jenny A.

AU - Welter, Jane C.

AU - Bharucha, Adil Eddie

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The Institute of Medicine and US Food and Drug Administration (FDA) recognize that activating clinical trials in the United States is lengthy and inefficient. Downstream consequences include increased expense, suboptimal accrual, move of clinical trials overseas, and delayed availability of treatments for patients. An in-tandem processing initiative is here highlighted that transformed the activation of clinical trials (TACT), reduced the activation time by 70%, and offers a paradigm for enhanced translational readiness.

AB - The Institute of Medicine and US Food and Drug Administration (FDA) recognize that activating clinical trials in the United States is lengthy and inefficient. Downstream consequences include increased expense, suboptimal accrual, move of clinical trials overseas, and delayed availability of treatments for patients. An in-tandem processing initiative is here highlighted that transformed the activation of clinical trials (TACT), reduced the activation time by 70%, and offers a paradigm for enhanced translational readiness.

UR - http://www.scopus.com/inward/record.url?scp=85038406650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038406650&partnerID=8YFLogxK

U2 - 10.1002/cpt.898

DO - 10.1002/cpt.898

M3 - Article

C2 - 29105757

AN - SCOPUS:85038406650

VL - 103

SP - 43

EP - 46

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 1

ER -